Send to

Choose Destination
  • Filters activated: Field: Title Word. Clear all
Alzheimers Dement (N Y). 2018 Apr 26;4:165-172. doi: 10.1016/j.trci.2018.03.006. eCollection 2018.

Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites.

Author information

Department of Neurology, Massachusetts General Hospital/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Mathematics and Statistics, University of Vermont, Burlington, VT, USA.
Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
Department of Psychiatry, Indiana University, Indianapolis, IA, USA.
Division of Cardiology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.
Section of Cardiology, Department of Medicine, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA.



The relationship between serum galectin-3 and incident cognitive impairment was analyzed in the Reasons for Geographic and Racial Differences in Stroke study.


Baseline galectin-3 was measured in 455 cases of incident cognitive impairment and 546 controls. Galectin-3 was divided into quartiles based on the weighted distribution in the control group, and the first quartile was the referent.


There was an increasing odds of cognitive impairment across quartiles of galectin-3 (odds ratios, 1.00 [0.68-1.46], 1.45 [1.01-2.10], and 1.58 [1.10-2.27] relative to the quartile 1; P trend = .003) in an unadjusted model, which persisted after adjusting for age, sex, and race (P = .004). Adjustment for cardiovascular risk factors greatly attenuated this association (odds ratios, 0.97 [0.60-1.57], 1.52 [0.94-2.46], and 1.27 [0.76-2.12]; P = .15). The association differed by diabetes status (P interaction, .007). Among nondiabetics (293 cases, 411 controls), those with galectin-3 in the fourth compared with first quartile had an odds ratio of 1.6 (0.95-2.99; P trend, .02). In diabetics, the odds ratio was 0.23 (0.04-1.33).


Serum galectin-3 was associated with increased risk of incident cognitive impairment in a large cohort study of blacks and whites but only in nondiabetics.


Biomarkers; Cognitive impairment; Epidemiology; Galectin-3; Incidence; Risk factors

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center